Swedish Orphan Biovitrum AB (publ) (Sobi) (STO: SOBI) announced today that the company has decided to exercise its opt-in right to take over final development and commercialisation of Elocta (rFVIIIFc) for the territory composed of Europe, North Africa, Russia and most Middle Eastern markets. Elocta/Eloctate(TM) is a recombinant factor VIII Fc fusion protein product candidate for the treatment of haemophilia A. Sobi will make a payment to Biogen Idec of USD 10 million, which will be held in escrow pending the EU regulatory approval of Elocta. Details about this and other compensation are described in the Collaboration Agreement section below. "This is an important milestone for Sobi and the result of a strong collaboration between our two companies," said Geoffrey McDonough, CEO at Sobi. "Sobi's legacy in haemophilia and rare diseases provides a platform for making this innovative treatment available for people with haemophilia A in our territory." Biogen Idec and Sobi are long-time collaborators in the development and commercialisation of Elocta/Eloctate for haemophilia A. Biogen Idec leads development for Elocta/Eloctate, has manufacturing rights, and has commercialisation rights in North America and all other regions excluding the Sobi territories. On 31 October 2014 Sobi and Biogen Idec announced that the European Medicines Agency (EMA) validated the Marketing Authorisation Application (MAA) for Elocta. The validation of the MAA initiated the EMA's review process. Elocta is the European trade name for rFVIIIFc, also known as Eloctate [Antihemophilic Factor (Recombinant), Fc Fusion Protein] in the U.S., Canada, and Australia, where it is approved for the treatment of haemophilia A. Elocta/Eloctate is the first recombinant clotting factor VIII therapy with prolonged circulation to provide protection from bleeding episodes with the potential for an extended interval between prophylactic injections. --- About Haemophilia A Haemophilia A is a rare, chronic, genetic disorder in which the ability of a person's blood to clot is impaired, due to missing or reduced levels of a protein known as factor VIII. People with haemophilia A experience bleeding episodes that may cause pain, irreversible joint damage and life-threatening haemorrhages. The World Federation of Hemophilia global survey conducted in 2012 estimates that approximately 142,000 people worldwide are identified as living with haemophilia A. About Elocta/Eloctate Elocta/Eloctate is an investigational, recombinant clotting factor therapy developed for haemophilia A by fusing factor VIII to the Fc portion of immunoglobulin G subclass 1, or IgG1 (a protein commonly found in the body). It is believed that this enables Elocta/Eloctate to use a naturally occurring pathway to prolong the time therapy remains in the body. While Fc fusion has been used for more than 15 years, Biogen Idec is the only company to apply it to the treatment of haemophilia. About the Biogen Idec and Sobi Collaboration To exercise its opt-in right to take over final development and commercialization of Elocta for its territory, Sobi will now make a payment into escrow of USD 10 million. Upon EU regulatory approval of Elocta, Sobi will be liable to repay approximately half of the development and manufacturing costs for Elocta/Eloctate incurred by Biogen Idec to date (approximately USD 180 million), as well as for additional investments made until Sobi formally assumes responsibility as the Marketing Authorization Holder for Elocta. Sobi estimates the total repayment obligation to reach approximately USD 240 million. The base royalty structure under the agreement states that Sobi will pay Biogen Idec 12% of direct sales in the Sobi territory, and Biogen Idec will pay Sobi 12% of direct sales in North America and 17% of direct sales in other markets. For Sobi to meet its repayment obligation, the base royalty structure will be adjusted during a repayment period beginning at the time of the first commercial sale in the Sobi territory, with the difference between the base royalties and the adjusted royalties being credited to Sobi's repayment obligation. According to the adjusted schedule Sobi will pay Biogen Idec a 17% royalty on direct sales in the Sobi territory, and Biogen Idec will pay Sobi a 7% royalty on direct sales in the Biogen Idec North America territory, and up to 12% in other markets. Upon complete repayment or July 2020, whichever comes sooner, the base 12% cross-royalty structure will apply. The cross-royalty and collaboration structure is described in detail in the Sobi press release dated 2012-02-06 "Sobi's agreement with Biogen Idec regarding long-lasting rFVIIIFc and rFIXFc hemophilia programs". (http://www.sobi.com/en/Investors--Media/News/RSS/? RSS=http://cws.huginonline.com/S/134557/PR/201202/1582735.xml) About Sobi Sobi is an international specialty healthcare company dedicated to rare diseases. Sobi's mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Inflammation and Genetic diseases, with two late stage biological development projects within Haemophilia. Sobi also markets a portfolio of specialty and rare disease products for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2013, Sobi had total revenues of SEK 2.2 billion (€253 M) and about 550 employees. The share (STO: SOBI) is listed on NASDAQ OMX Stockholm. More information is available at www.sobi.com. For more information please contact Sobi Media Contact: Charlotte af Klercker T: +46 70 7 297 327 charlotte.afklercker@sobi.com Investor Relations contact: Jörgen Winroth T: +1 347-224-0819, +1 212-579-0506 jorgen.winroth@sobi.com [HUG#1873208]
Sobi exercises opt-in right for Elocta(TM) Swedish Orphan
Top 10 Most Recent News Articles
Berlin Heals Puts Microcurrent Therapy to a Real Test
A silent electrical signal is heading into the sort of trial that separates intriguing ideas from credible medical evidence. Berlin Heals Holding AG has initiated C-MIC IV, an international randomized, double-blind, sham-controlled study of its implanted microcurrent therapy for symptomatic heart failure. The first patient has already been implanted in Kragujevac, Serbia....
Continue Reading
Ideas Abu Dhabi Puts Water Innovation on Stage
Water rarely gets the spotlight until a pipe fails, a harvest shrinks, or a city starts rationing. That is why the agenda around Ideas Abu Dhabi at the 2026 UN Water Conference deserves more than the usual polite nod given to conference programming. From 7 to 10 December in Abu Dhabi, this is shaping up as a public-facing attempt to connect a hard physical problem with...
Continue Reading
Albany Masonry Waterproofing Is a Quiet Value Play
Winter works its mischief one soaked brick at a time. That is the unglamorous truth behind Sean Mulligan's discussion of masonry waterproofing for Albany-area homes. Brick and stone look tough enough to outlast the furniture, the siding, maybe the whole neighborhood. Yet they are porous materials, and in a region where rain, snowmelt, and sharp temperature swings keep...
Continue Reading
Fidelis Puts $140,000 Behind Statewide Postpartum Care
A missed postpartum appointment can look like a small administrative failure until it is not. Fidelis Care’s $140,000 round of Here for Your Health maternal health grants is aimed squarely at that unglamorous but consequential gap: keeping new mothers connected to care after delivery, particularly in underserved New York communities. Small Dollars, Very Specific...
Continue Reading
Teachers in Space Takes Its Classroom Model Orbital
Two teachers strapped into a research flight may sound like a glossy space-age photo op, but the useful part of this plan sits back in the classroom with the students staring at the data. Teachers in Space wants to send two educators aboard a Virgin Galactic research flight expected in 2027, and it is raising $2 million to fund the broader educational program and mission....
Continue Reading
Physiatry or Orthopedics: Sorting Out Pain Care Choices
Pain care gets muddled the minute people assume every ache needs the same doorway. Dr. Mala Young, a physical medicine and rehabilitation expert in Ann Arbor, Michigan, makes a useful distinction: a physiatrist and an orthopedic doctor may both see pain, mobility trouble, and injury, but they are not interchangeable. That sounds obvious until someone is staring at back...
Continue Reading
Gozney Brings in Armin Boehm for a Global Growth Push
A pizza oven company has just made a very grown-up management move. Gozney appointed Armin Boehm as Global President, effective from October 31, putting an experienced consumer-brand operator beside founder, designer and CEO Tom Gozney at a moment when the business says it is becoming a global omnichannel operation. This is not the sort of announcement that comes with...
Continue Reading
TGHL Eyes U.S. Battery Shift Through EnChem Merger
A Policy Squeeze Is Rewriting the Battery Map Battery supply chains are getting shoved through a narrower gate, and that is exactly why this proposed deal deserves a hard look. The GrowHub Limited wants to acquire EnChem America, a Georgia-based lithium-ion battery electrolyte producer, and the timing is plainly built around Washington's push to reduce reliance on...
Continue Reading
Receipts Turns Vegas Party Shirts Into AR Keepsakes
A shirt that coughs up a Vegas weekend when scanned is either a smart little keepsake trick or a privacy headache wearing sequins. Receipts™, introduced by Las Vegas-based Naked City Couture and the AR Trading Card Company, is betting it can be the former. The concept is simple enough: friends wear the apparel, capture photos and videos during a trip, upload those...
Continue Reading
Vertex Extends Genomics Pact With $220M in Potential
Eight years is long enough to separate a useful science partner from a glossy slide deck, and Vertex’s decision to add four more years with Genomics deserves attention. This is not a splashy acquisition, nor is it a clean revenue number investors can plug into next quarter’s model. It is a deeper commitment to the slow, expensive, wonderfully unforgiving business of...
Continue ReadingTop 5 Most Recently Viewed Articles
Impact of Withdrawal on Menthol Cigarette Regulation Efforts
The Trump Administration's Recent Decision Recently, the Trump administration made headlines by withdrawing a previously proposed ban on menthol cigarettes in the United States. This decision marks a significant setback for health regulators and activists who have long been advocating for healthier tobacco policies. Background of the Proposal In April 2022, the Food and...
Continue Reading
Carta Healthcare Secures Gold by Innovating Clinical Data
Tackling a Stubborn Healthcare Pain Point Let's face it: the healthcare industry's data management game has been sweating buckets over a Herculean task for years. A staggering $10-15 billion gets burned annually thanks to inefficient clinical data abstraction. Today's hero of this tale? Carta Healthcare, which just snagged a shining Gold at the 2026 Stevie Awards in...
Continue Reading
SentinelOne Earns Prestigious Recognition from Gartner for 2024
SentinelOne's Recent Achievement in Cloud Security SentinelOne (NYSE: S), a prominent player in the field of AI-driven security solutions, has recently been acknowledged as a Customers' Choice in the 2024 Gartner® Peer Insights™ report specifically for Cloud-Native Application Protection Platforms. This recognition reflects feedback from a broad user base, emphasizing...
Continue Reading
Tingus Goose: A Premium Idle Game Experience on Steam
Exciting Announcement for Gamers The cult phenomenon, Tingus Goose, is making its debut on Steam as a fully enhanced 1.0 edition designed for PC players. Co-published by Playsaurus and Ultraplayers, this adaptation aims to deliver the ultimate idle gaming experience, free from the distractions found in mobile versions. What’s New in Tingus Goose? Unique Gameplay...
Continue ReadingTrackerRMS Launches Innovative Onboarding+ Solution for Staffing
Introducing the New Onboarding+ Solution by TrackerRMS TrackerRMS has taken a significant step in revolutionizing the recruitment landscape with the introduction of its Onboarding+ solution. This innovative tool is designed specifically for recruitment agencies looking to enhance their onboarding process and improve the overall candidate journey. By integrating advanced...
Continue Reading